Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma

Journal of Translational Medicine

Rong-ping Guo¹  Ming Shi¹  Zhi-xing Guo²  Wei Wei¹  Jia-hong Wang¹ 

[1] Department of Hepatobilliary Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou 510060, P. R. China;Department of Ultrasonics, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

关键词: Prognosis;    Aggressiveness;    MMP-9;    Cezanne;    Hepatocellular carcinoma;   

Others  :  1137656
DOI  :  10.1186/s12967-015-0396-1

 received in 2014-10-29, accepted in 2015-01-14,  发布年份 2015

【 摘 要 】

Background

Deubiquitinases, such as CYLD, A20 and Cezanne, have emerged as negative regulators that balance the strength and duration of NF-κB signaling through feedback mechanisms. However, how these serial feedback loops are simultaneously disrupted in cancer remains unclear. The purpose of this study is to investigate the correlation of Cezanne expression with clinicopathological/prognostic value in hepatocellular carcinoma (HCC).

Methods

The expression levels of Cezanne and matrix metallopeptidase 9 (MMP-9) were assessed by immunohistochemistry in 230 HCC specimens. The correlation between expression of Cezanne and MMP-9, clinicopathological/prognostic value in hepatocellular carcinoma was examined.

Results

Cezanne reduction in HCC was significantly associated with larger tumor, satellite nodule, vascular invasion, TNM stage, BCLC stage and early recurrence. Kaplan-Meier analysis showed that Cezanne was a great predictive factor for overall survival (OS) and time to recurrence (TTR). The expression of Cezanne was decreased in TNM and BCLC stage-dependent manner. In addition, Cezanne reduction was associated with poor prognosis in patients subgroups stratified by tumor size, tumor differentiation, TNM stage and BCLC stage. Moreover, Cezanne was negatively associated with MMP-9 among 230 HCC samples. Patients who had Cezanne downregulation, in which cancer cells showed high invasiveness, had shorter TTR and poor OS. Furthermore, the coindex of Cezanne and preoperative serum AFP levels was significantly correlated with OS and TTR.

Conclusion

Cezanne has a pivotal role in tumor progression and prognosis, and may act as a potential prognostic biomarker for survival in HCC patients.

【 授权许可】

   
2015 Wang et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [2]El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-76.
• [3]Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, et al.: Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007, 25(21):3069-75.
• [4]Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al.: Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006, 243(2):229-35.
• [5]Aravalli RN, Steer CJ, Cressman EN: Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008, 48(6):2047-63.
• [6]Dragani TA: Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010, 52(2):252-7.
• [7]Ma WW, Adjei AA: Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009, 59(2):111-37.
• [8]Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48(4):1312-27.
• [9]Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al.: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008, 135(6):1972-83. 1983 e1971-1911
• [10]Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-80.
• [11]Nikolaou K, Sarris M, Talianidis I: Molecular pathways: the complex roles of inflammation pathways in the development and treatment of liver cancer. Clin Cancer Res 2013, 19(11):2810-6.
• [12]He G, Karin M: NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011, 21(1):159-68.
• [13]Hoesel B, Schmid JA: The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013, 12:86. BioMed Central Full Text
• [14]Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, et al.: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004, 430(7000):694-9.
• [15]Evans PC, Smith TS, Lai MJ, Williams MG, Burke DF, Heyninck K, et al.: A novel type of deubiquitinating enzyme. J Biol Chem 2003, 278(25):23180-6.
• [16]Enesa K, Zakkar M, Chaudhury H, le Luong A, Rawlinson L, Mason JC, et al.: NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J Biol Chem 2008, 283(11):7036-45.
• [17]La Starza R, Crescenzi B, Pierini V, Romoli S, Gorello P, Brandimarte L, et al.: A common 93-kb duplicated DNA sequence at 1q21.2 in acute lymphoblastic leukemia and Burkitt lymphoma. Cancer Genet Cytogenet 2007, 175(1):73-6.
• [18]Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, et al.: Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996, 24(2):316-22.
• [19]Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al.: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006, 131(2):461-9.
• [20]Sun B, Karin M: NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 2008, 27(48):6228-44.
• [21]Arsura M, Cavin LG: Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 2005, 229(2):157-69.
• [22]Maeda S, Omata M: Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci 2008, 99(5):836-42.
• [23]Jia W, Gao XJ, Zhang ZD, Yang ZX, Zhang G: S100A4 silencing suppresses proliferation, angiogenesis and invasion of thyroid cancer cells through downregulation of MMP-9 and VEGF. Eur Rev Med Pharmacol Sci 2013, 17(11):1495-508.
• [24]Yeh MH, Kao ST, Hung CM, Liu CJ, Lee KH, Yeh CC: Hesperidin inhibited acetaldehyde-induced matrix metalloproteinase-9 gene expression in human hepatocellular carcinoma cells. Toxicol Lett 2009, 184(3):204-10.
• [25]Yu HB, Zhang HF, Li DY, Zhang X, Xue HZ, Zhao SH: Matrine inhibits matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. J Asian Nat Prod Res 2011, 13(3):242-50.
• [26]Kanki K, Akechi Y, Ueda C, Tsuchiya H, Shimizu H, Ishijima N, et al.: Biological and clinical implications of retinoic acid-responsive genes in human hepatocellular carcinoma cells. J Hepatol 2013, 59(5):1037-44.
• [27]Song L, Lin C, Gong H, Wang C, Liu L, Wu J: miR-486 sustains NF-kappaB activity by disrupting multiple NF-kappaB-negative feedback loops. Cell Res 2013, 23(2):274-89.
• [28]Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 18(5):1135-49.
• [29]Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14(2):163-76.
• [30]Chen R, Cui J, Xu C, Xue T, Guo K, Gao D, et al.: The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol 2012, 19(Suppl 3):S375-84.
• [31]Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, et al.: Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003, 23(2C):1747-53.
• [32]Johnson PJ: The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001, 5(1):145-59.